Photodynamic therapy (PDT), a therapeutic mode involving light triggering, has been
recognized as an attractive oncotherapy treatment. However, nonnegligible challenges …

NAMI-A ((ImH)[trans-RuCl4 (dmso-S)(Im)], Im= imidazole) and KP1019/1339
(KP1019=(IndH)[trans-RuCl4 (Ind) 2], Ind= indazole; KP1339= Na [trans-RuCl4 (Ind) 2]) are …

As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …

Summary Background This phase I/II study determined the maximal tolerable dose, dose
limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of …

The study of metal complexes for the treatment of cancer diseases has resulted in the
identification of some unique properties of ruthenium-based compounds. Among these …

The well-developed synthetic chemistry of ruthenium, particularly with ammine, amine and
imine ligands, provides for many approaches to innovative new metallopharmaceuticals …

Since the discovery of cis-platinum, many transition metal complexes have been
synthesized and assayed for antineoplastic activity. In recent years, ruthenium-based …

Abstract Purpose: NAMI-A {H2Im [trans-RuCl4 (DMSO) HIm] or imidazolium-trans-DMSO-
imidazole-tetrachlororuthenate} is a novel ruthenium-containing compound that has …

Despite their past triumphs, platinum-based therapeutics remain limited by chemo-
resistance and severe side effects. As an alternative therapeutic modality which bypasses …

Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and
two of them have entered clinical trials. Compared to platinum drugs, the complexes based …